TIDMSCLP

RNS Number : 0261L

Scancell Holdings Plc

27 April 2020

27 April 2020

Scancell Holdings plc

("Scancell" or the "Company")

Director Dealing

Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer announces that Vulpes Life Science Fund, a person closely associated with Martin Diggle, Non- Executive Director, has sold 500,000 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 24 April 2020 at a price of 8p per share. Following the sale, Vulpes Life Science Fund holds 80,049,311 ordinary shares representing 17.2% of the company.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Vulpes Life Science Fund 
     -------------------------------  ---------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------------- 
 a)   Position/status                  Person closely associated with Martin Diggle, 
                                        Non-Executive Director 
     -------------------------------  ---------------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------------- 
 a)   Name                             Scancell Holdings plc 
     -------------------------------  ---------------------------------------------- 
 b)   LEI                              2138008RXEG856SNP666 
     -------------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.1 pence each 
       financial instrument, 
       type of instrument 
     -------------------------------  ---------------------------------------------- 
 b)   Identification Code              GB00B63D3314 
     -------------------------------  ---------------------------------------------- 
 c)   Nature of the transaction        Sale of Ordinary Shares 
     -------------------------------  ---------------------------------------------- 
 
 d)   Price(s) and volume(s)           500,000 Ordinary Shares 
                                        8 pence per Ordinary Share 
     -------------------------------  ---------------------------------------------- 
 e)   Aggregated information 
       - Aggregated volume               N/A (single transaction) 
       - Price 
     -------------------------------  ---------------------------------------------- 
 f)   Date of the transaction          24 April 2020 
     -------------------------------  ---------------------------------------------- 
 g)   Place of the transaction         London Stock Exchange, AIM 
     -------------------------------  ---------------------------------------------- 
 

- ENDS -

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For more information, please contact:

 
                                                   +44 (0)20 3727 
 Scancell Holdings plc                              1000 
 Dr John Chiplin, Chairman 
 Dr Cliff Holloway, CEO 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    +44 (0) 20 7886 
  and Joint Broker)                                 2500 
 Corporate Finance: Freddy Crossley, Emma 
  Earl 
 Corporate Broking: James Stearns 
 
                                                   +44 (0)20 3727 
 FTI Consulting                                     1000 
 Simon Conway 
 Natalie Garland-Collins 
 

Notes for Editors

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

-- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

-- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope(R) represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope(R) alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

-- Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab(TM) is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19. The Company believes this combined T cell and antibody approach should give more potent and long-lasting responses, ultimately leading to better protection.

For further details, please see our website: www.scancell.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEASLXADKEEFA

(END) Dow Jones Newswires

April 27, 2020 11:39 ET (15:39 GMT)

Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Scancell
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Scancell